Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Like many pharma stocks, Eli Lilly (NYSE ... I'm talking about weight loss drugs. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

The weight loss potential is not exactly there to match the likes of Eli Lilly’s tirzepatide or Novo Nordisk’s CagriSema which has an amylin analog as a “performance enhancer” on top of ...

March 12 (Reuters) - U.S. drugmakers Johnson & Johnson (JNJ.N), opens new tab and Eli Lilly (LLY.N), opens new tab increased spending on security for their top executives in 2024, citing increased ...

A Texas court ruled last week that the FDA can declare the shortage of Eli Lilly's Zepbound is over. In a clarification Monday, FDA gave compounders until March 19, 2025 to cease selling Zepbound ...